ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...

ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer ...

ImmunityBio (IBRX) added ~7% in the premarket on Wednesday after the company announced that the National Comprehensive Cancer Network has updated its treatment guidelines to include an expanded use of ...

Life-saving treatments for children with orphan illnesses often move slowly, if at all, through the federal approval process.

Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.

Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...

Congenital lower urinary tract obstruction, often presenting as fetal megacystis, is defined in the first trimester by a longitudinal bladder diameter greater than 7 mm on ultrasonography. It most ...

Colorblindness may be doing more than making traffic lights confusing — it could also be hiding a life-threatening warning sign. Researchers analyzing millions of medical records found that people ...

Liquid biopsy guided disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer (DECIDING-I study). This is an ASCO Meeting ...

Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA. pTisN0 7 4.1 (1.7–8.3) 2 ...

Management of Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer (BCG-unresponsive NMIBC) is rapidly evolving, with an expanding range of bladder-sparing therapies challenging ...